The role of immune reconstitution in relapse after allogeneic hematopoietic stem cell transplantation

References

• Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese society of hematology. J Hematol Oncol. 2018;11(1):1–17. doi: 10.1186/s13045-018-0564-x
   PubMed Web of Science ®Google Scholar
• Chang YJ, Pei XY, Huang XJ. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions. Lancet Haematol. 2022;9(12):e919–e929.
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert Rev Hematol. 2010;3(4):429–441. doi: 10.1586/ehm.10.32
   PubMed Web of Science ®Google Scholar
• Guru Murthy GS, Kim S, Hu ZH, et al. Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors. JAMA Oncol. 2022;8(3):404–411. doi: 10.1001/jamaoncol.2021.6846
   PubMed Web of Science ®Google Scholar
• Gambacorta V, Beretta S, Ciccimarra M, et al. Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse. Cancer Discov. 2022;12(6):1449–1461. doi: 10.1158/2159-8290.CD-21-0980
   PubMed Web of Science ®Google Scholar
• Summers C, Sheth VS, Bleakley M. Minor Histocompatibility Antigen-Specific T Cells. Front Pediatr. 2020;8. doi: 10.3389/fped.2020.00284
   PubMed Web of Science ®Google Scholar
• Shouval R, Fein JA, Labopin M, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European society for blood and marrow transplantation registry retrospective analysis. Lancet Haematol. 2019;6(11):e573–e584. doi: 10.1016/S2352-3026(19)30158-9
   PubMed Web of Science ®Google Scholar
• Sugiyanto M, Gosal S, Kosim A, et al. Impact of the source of hematopoietic stem cells on immune reconstitution after transplantation: a systematic review. Eur J Haematol. 2023;111(1):4–14. doi: 10.1111/ejh.13966
   PubMed Web of Science ®Google Scholar
• Ogonek J, Juric MK, Ghimire S, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7: doi: 10.3389/fimmu.2016.00507
   Web of Science ®Google Scholar
• Ando T, Tachibana T, Tanaka M, et al. Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation. Blood Adv. 2020;4(2):408–419. doi: 10.1182/bloodadvances.2019001021
   PubMed Web of Science ®Google Scholar
• Arruda LCM, Gaballa A, Uhlin M. Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis. Blood Adv Am J Hematol. 2019;3(21):3436–3448. doi: 10.1182/bloodadvances.2019000682
   PubMed Web of Science ®Google Scholar
• Danby R, Rocha V. Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol. 2014;5. doi: 10.3389/fimmu.2014.00068
   PubMed Web of Science ®Google Scholar
• Elfeky R, Lazareva A, Qasim W, et al. Immune reconstitution following hematopoietic stem cell transplantation using different stem cell sources. Expert Rev Clin Immunol. 2019;15(7):735–751. doi: 10.1080/1744666X.2019.1612746
   PubMed Web of Science ®Google Scholar
• Huo Y, Wu L, Pang A, et al. Single-cell dissection of human hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation. Sci Immunol. 2023;8(81):8. doi: 10.1126/sciimmunol.abn6429
   Web of Science ®Google Scholar
• Pandey RV, Strobl J, Redl A, et al. Epigenetic regulation of T cell lineages in skin and blood following hematopoietic stem cell transplantation. Clin Immunol. 2023;248:109245. doi: 10.1016/j.clim.2023.109245
   PubMed Web of Science ®Google Scholar
• Savage WJ, Bleesing JJH, Douek D, et al. Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism. Bone Marrow Transplant. 2001;28(5):463–471. doi: 10.1038/sj.bmt.1703176
   PubMed Web of Science ®Google Scholar
• Fedele R, Martino M, Garreffa C, et al. The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfus. 2012;10(2):174–180. doi: 10.2450/2012.0034-11
   PubMed Web of Science ®Google Scholar
• Massoud R, Klyuchnikov E, Gagelmann N, et al. Impact of anti-T-lymphocyte globulin dosing on GVHD and immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation. Bone Marrow Transplant. 2022;57(10):1548–1555. doi: 10.1038/s41409-022-01666-x
   PubMed Web of Science ®Google Scholar
• Parkman R, Cohen G, Carter SL, et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2006;12(9):919–927. doi: 10.1016/j.bbmt.2006.05.008
   PubMed Web of Science ®Google Scholar
• Ranti J, Kurki S, Salmenniemi U, et al. Early CD8 + -recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT. PLoS One. 2018;13(9):13. doi: 10.1371/journal.pone.0204136
   Web of Science ®Google Scholar
• Foley B, Cooley S, Verneris MR, et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood. 2011;118(10):2784–2792. doi: 10.1182/blood-2011-04-347070
   PubMed Web of Science ®Google Scholar
• Sun YQ, Chang YJ, Huang XJ. Update on current research into haploidentical hematopoietic stem cell transplantation. Expert Rev Hematol. 2018;11(4):273–284. doi: 10.1080/17474086.2018.1447379
   PubMed Web of Science ®Google Scholar
• Zhou Z, Liu X, Zhang X, et al. Impact of early natural killer cell reconstitution on the outcomes of T cell-replete allogeneic hematopoietic stem cell transplantation. J Inflamm Res. 2023;16:2993–3008. doi: 10.2147/JIR.S416708
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-Mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333–339. doi: 10.1182/blood.V94.1.333.413a31_333_339
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100. doi: 10.1126/science.1068440
   PubMed Web of Science ®Google Scholar
• Pical-Izard C, Crocchiolo R, Granjeaud S, et al. Reconstitution of natural killer cells in HLA-Matched HSCTafter reduced-intensity conditioning: impact on ClinicalOutcome. Biol Blood Marrow Transplant. 2015;21(3):429–439. doi: 10.1016/j.bbmt.2014.11.681
   PubMed Web of Science ®Google Scholar
• Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant. 2008;14(3):323–334. doi: 10.1016/j.bbmt.2007.12.497
   PubMed Web of Science ®Google Scholar
• McCurdy SR, Radojcic V, Tsai HL, et al. Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022;139(4):608–623. doi: 10.1182/blood.2021013054
   PubMed Web of Science ®Google Scholar
• Li L, Chen H, Marin D, et al. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv. 2019;3(23):4117–4130. doi: 10.1182/bloodadvances.2019000835
   PubMed Web of Science ®Google Scholar
• Cooley S, Parham P, Miller JS. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood. 2018;131(10):1053–1062. doi: 10.1182/blood-2017-08-752170
   PubMed Web of Science ®Google Scholar
• Gao F, Ye Y, Gao Y, et al. Influence of KIR and NK cell reconstitution in the outcomes of hematopoietic stem cell transplantation. Front Immunol. 2020;11: doi: 10.3389/fimmu.2020.02022
   Web of Science ®Google Scholar
• Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol Internet. 2004;172(1):644–650. doi: 10.4049/jimmunol.172.1.644
   PubMed Web of Science ®Google Scholar
• Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3):726–732. doi: 10.1182/blood-2008-07-171926
   PubMed Web of Science ®Google Scholar
• Ye W, Kong X, Zhang W, et al. The roles of γδ T cells in hematopoietic stem cell transplantation. Cell Trans. 2020;29. doi: 10.1177/0963689720966980
   PubMed Web of Science ®Google Scholar
• Maniar A, Zhang X, Lin W, et al. Human γδ T lymphocytes induce robust NK cell–mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010;116(10):1726–1733. doi: 10.1182/blood-2009-07-234211
   PubMed Web of Science ®Google Scholar
• Meuter S, Eberl M, Moser B. Prolonged antigen survival and cytosolic export in cross-presenting human γδ T cells. Proc Natl Acad Sci U S A. 2010;107(19):8730–8735. doi: 10.1073/pnas.1002769107
   PubMed Web of Science ®Google Scholar
• Godder KT, Henslee-Downey PJ, Mehta J, et al. Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007;39(12):751–757. doi: 10.1038/sj.bmt.1705650
   PubMed Web of Science ®Google Scholar
• Minculescu L, Marquart HV, Ryder LP, et al. Improved overall survival, relapse-free-survival, and less graft-vs.-host-disease in patients with high immune reconstitution of TCR gamma delta cells 2 months after allogeneic stem cell transplantation. Front Immunol. 2019;10:1–18. doi: 10.3389/fimmu.2019.01997
   PubMed Web of Science ®Google Scholar
• Cunningham KT, Mills KHG. Trained innate immunity in hematopoietic stem cell and solid organ transplantation. Transplantation. 2021;105(8):1666–1676. doi: 10.1097/TP.0000000000003673
   PubMed Web of Science ®Google Scholar
• Beauvillain C, Delneste Y, Scotet M, et al. Neutrophils efficiently cross-prime naive T cells in vivo. Blood. 2007;110(8):2965–2973. doi: 10.1182/blood-2006-12-063826
   PubMed Web of Science ®Google Scholar
• Wachowska M, Wojciechowska A, Muchowicz A. The role of neutrophils in the pathogenesis of chronic lymphocytic leukemia. Int J Mol Sci MDPI. 2022;23(1):365. doi: 10.3390/ijms23010365
   Web of Science ®Google Scholar
• Turcotte LM, Cao Q, Cooley SA, et al. Monocyte subpopulation recovery as predictors of hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant. 2019;25(5):883–890. doi: 10.1016/j.bbmt.2019.01.003
   PubMed Web of Science ®Google Scholar
• Yu H, Tian Y, Wang Y, et al. Dendritic cell regulation of graft vs.-host disease: immunostimulation and tolerance immunostimulation. Front Immunol. 2019;10: doi: 10.3389/fimmu.2019.00093
   Web of Science ®Google Scholar
• Zaghi E, Calvi M, Di Vito C, et al. Innate immune responses in the outcome of haploidentical hematopoietic stem cell transplantation to cure hematologic malignancies. Front Immunol. 2019;10: doi: 10.3389/fimmu.2019.02794
   PubMed Web of Science ®Google Scholar
• Liu L, Chang Y-J, Xu L-P, et al. T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clin Immunol. 2018;190:32–40. doi: 10.1016/j.clim.2018.02.009
   PubMed Web of Science ®Google Scholar
• Liu L, Chang Y-J, Xu L-P, et al. Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after allo-HSCT. Biol Blood Marrow Transplant. 2018;24(7):1350–1359. doi: 10.1016/j.bbmt.2018.03.030
   PubMed Web of Science ®Google Scholar
• Guo H, Chang Y-J, Hong Y, et al. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol. 2021;18(5):1172–1185. doi: 10.1038/s41423-020-00597-1
   PubMed Web of Science ®Google Scholar
• Pei X, Zhao X, Wang Y, et al. Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts. Front Med. 2018;12(2):153–163. doi: 10.1007/s11684-017-0548-1
   PubMed Web of Science ®Google Scholar
• Yakoub-Agha I, Saule P, Magro L, et al. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse. Biol Blood Marrow Transplant. 2009;15(4):496–504. doi: 10.1016/j.bbmt.2008.11.038
   PubMed Web of Science ®Google Scholar
• Tian DM, Wang Y, Zhang XH, et al. Rapid recovery of CD3+CD8+ T cells on day 90 predicts superior survival after unmanipulated haploidentical blood and marrow transplantation. PLoS One. 2016;11(6):11. doi: 10.1371/journal.pone.0156777
   Web of Science ®Google Scholar
• Politikos I, Lavery JA, Hilden P, et al. Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. Blood Adv. 2020;4(1):191–202. doi: 10.1182/bloodadvances.2019000836
   PubMed Web of Science ®Google Scholar
• Merindol N, Champagne MA, Duval M, et al. CD8+ T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse. Blood. 2011;118(16):4480–4488. doi: 10.1182/blood-2011-04-349241
   PubMed Web of Science ®Google Scholar
• Chang YJ, Zhao XY, Huo MR, et al. Immune reconstitution following unmanipulated HLA-Mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol. 2012;32(2):268–280. doi: 10.1007/s10875-011-9630-7
   PubMed Web of Science ®Google Scholar
• Kim DH, Sohn SK, Won DI, et al. Rapid helper T-cell recovery above 200 × 106/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37(12):1119–1128. doi: 10.1038/sj.bmt.1705381
   PubMed Web of Science ®Google Scholar
• Troullioud Lucas AG, Lindemans CA, Bhoopalan SV, et al. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. Cytotherapy. 2023;25(9):977–985. doi: 10.1016/j.jcyt.2023.05.012
   PubMed Web of Science ®Google Scholar
• Bejanyan N, Brunstein CG, Cao Q, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018;2(8):909–922. doi: 10.1182/bloodadvances.2017014464
   PubMed Web of Science ®Google Scholar
• van Roessel I, Prockop S, Klein E, et al. Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. Cytotherapy. 2020;22(9):503–510. doi: 10.1016/j.jcyt.2020.05.005
   PubMed Web of Science ®Google Scholar
• Van Heijst JWJ, Ceberio I, Lipuma LB, et al. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. Nat Med. 2013;19(3):372–377. doi: 10.1038/nm.3100
   PubMed Web of Science ®Google Scholar
• Buhler S, Bettens F, Dantin C, et al. Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation. Leukemia. 2020;34(5):1422–1432. doi: 10.1038/s41375-019-0654-y
   PubMed Web of Science ®Google Scholar
• Chapuis AG, Egan DN, Bar M, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019;25(7):1064–1072. doi: 10.1038/s41591-019-0472-9
   PubMed Web of Science ®Google Scholar
• Sugiyama H. WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40(5):377–387. doi: 10.1093/jjco/hyp194
   PubMed Web of Science ®Google Scholar
• Roex MCJ, Hageman L, Veld SAJ, et al. A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity. Blood. 2020;136(4):455–467. doi: 10.1182/blood.2019004443
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102(8):2892–2900. doi: 10.1182/blood-2003-01-0150
   PubMed Web of Science ®Google Scholar
• Kapp M, Stevanović S, Fick K, et al. CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant. 2009;43(5):399–410. doi: 10.1038/bmt.2008.426
   PubMed Web of Science ®Google Scholar
• Hoegh-Petersen M, Sy S, Ugarte-Torres A, et al. High Epstein–barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation. Leukemia. 2012;26(2):359–362. doi: 10.1038/leu.2011.195
   PubMed Web of Science ®Google Scholar
• Gupta M, Kannappan S, Kalra A, et al. High incidence of hematologic malignancy relapse after allogeneic transplantation in patients with low Epstein-Barr virus–specific T-cell counts. Cytotherapy. 2019;21(8):886–894. doi: 10.1016/j.jcyt.2019.06.001
   PubMed Web of Science ®Google Scholar
• Luo XH, Poiret T, Liu Z, et al. Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: impact of CMV infection and leukemia relapse. Front Immunol. 2023;13: doi: 10.3389/fimmu.2022.1027593
   Google Scholar
• D’Sa S, Peggs K, Pizzey A, et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor ly. Br J Haematol. 2003;123(2):309–322. doi: 10.1046/j.1365-2141.2003.04612.x
   PubMed Web of Science ®Google Scholar
• Van Der Maas NG, Berghuis D, Van Der Burg M, et al. B cell reconstitution and influencing factors after hematopoietic stem cell transplantation in children. Front Immunol. 2019. doi: 10.3389/fimmu.2019.00782
   Web of Science ®Google Scholar
• Chang YJ, Wang Y, Xu LP, et al. Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol. 2020;13(1):1–13. doi: 10.1186/s13045-020-00860-y
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schmid C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767–776. doi: 10.1182/blood-2003-02-0342
   PubMed Web of Science ®Google Scholar
• Zheng X, Tian Z. Which is better, HLA-matched sibling or haploidentical transplantation? Cell Mol Immunol. 2021;18(5):1347. doi: 10.1038/s41423-021-00640-9
   PubMed Web of Science ®Google Scholar
• Pei XY, Zhao XY, Chang YJ, et al. Cytomegalovirus-specific T-Cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 2017;216(8):945–956. doi: 10.1093/infdis/jix357
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013;122(7):1316–1324. doi: 10.1182/blood-2013-02-487074
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118(5):1402–1412. doi: 10.1182/blood-2010-08-304121
   PubMed Web of Science ®Google Scholar
• de Witte MA, Sarhan D, Davis Z, et al. Early reconstitution of NK and γδ T cells and its implication for the design of post-transplant immunotherapy. Biol Blood Marrow Transplant. 2018;24(6):1152–1162. doi: 10.1016/j.bbmt.2018.02.023
   PubMed Web of Science ®Google Scholar
• Cichocki F, Cooley S, Davis Z, et al. CD56dim CD57+ NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2016;30(2):456–463. doi: 10.1038/leu.2015.260
   PubMed Web of Science ®Google Scholar
• Knight A, Madrigal AJ, Grace S, et al. The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood. 2010;116(12):2164–2172. doi: 10.1182/blood-2010-01-255166
   PubMed Web of Science ®Google Scholar
• De Koning C, Nierkens S, Boelens JJ. Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution. Blood. 2016;128(23):2607–2615. doi: 10.1182/blood-2016-06-724005
   PubMed Web of Science ®Google Scholar
• Kolb H, Schattenberg A, Goldman J, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia [see comments]. Blood. 1995;86(5):2041–2050. doi: 10.1182/blood.V86.5.2041.bloodjournal8652041
   PubMed Web of Science ®Google Scholar
• Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom? Blood Rev. 2013;27(1):55–62. doi: 10.1016/j.blre.2012.11.002
   PubMed Web of Science ®Google Scholar
• Yan C-H, Liu Q, Wu D, et al. Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease–guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia. Biol Blood Marrow Transplant. 2017;23(8):1311–1319. doi: 10.1016/j.bbmt.2017.04.028
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong ASM, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(1):236–242. doi: 10.1182/blood-2007-08-108241
   PubMed Web of Science ®Google Scholar
• Naik S, Vasileiou S, Tzannou I, et al. Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL. Blood. 2022;139(17):2706–2711. doi: 10.1182/blood.2021014648
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi: 10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• Dagar G, Gupta A, Masoodi T, et al. Correction: harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 2023;21(1):1–36. doi: 10.1186/s12967-023-04404-z
   PubMed Web of Science ®Google Scholar
• Schubert ML, Schmitt A, Hückelhoven-Krauss A, et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol. 2023;16(1):1–17. doi: 10.1186/s13045-023-01470-0
   PubMed Web of Science ®Google Scholar
• Van Elssen CHMJ, Ciurea SO. NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect? Int J Hematol. 2018;107:151–156. doi: 10.1007/s12185-017-2379-x
   PubMed Web of Science ®Google Scholar
• Shah NN, Baird K, Delbrook CP, et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation. Blood. 2015;125(5):784–792. doi: 10.1182/blood-2014-07-592881
   PubMed Web of Science ®Google Scholar
• Lee KH, Yoon SR, Gong JR, et al. The infusion of ex vivo, interleukin-15 and-21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients—a randomized trial. Leukemia. 2023;37(4):807–819. doi: 10.1038/s41375-023-01849-5
   PubMed Web of Science ®Google Scholar
• Franzke A. The role of G-CSF in adaptive immunity. Cytokine Growth Factor Rev. 2006;17(4):235–244. doi: 10.1016/j.cytogfr.2006.05.002
   PubMed Web of Science ®Google Scholar
• Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361–3369. doi: 10.1182/blood-2011-09-377044
   PubMed Web of Science ®Google Scholar
• Huang J, Hong M, Zhu Y, et al. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia. Leuk Lymphoma. 2018;59(11):2570–2579. doi: 10.1080/10428194.2018.1443328
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-Negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020;38(36):4249–4259. doi: 10.1200/JCO.19.03277
   PubMed Web of Science ®Google Scholar
• Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87(6):2195–2204. doi: 10.1182/blood.V87.6.2195.bloodjournal8762195
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Fefer A, Sandmaier BM, et al. A Phase I/ii study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(9):1308–1315. doi: 10.1016/j.bbmt.2011.01.004
   PubMed Web of Science ®Google Scholar
• Zhang Q, Hresko ME, Picton LK, et al. A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci Transl Med. 2021;13(625). doi: 10.1126/scitranslmed.abg6986
   Web of Science ®Google Scholar
• Thiolat Allanand Pilon C and CP and MA and TNH and SC and LM and MS and PE and CJL versusTreg-targeted IL-2/anti-IL-2 complex controls graft–host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation. Haematologica. 2023. Online ahead of print. doi: 10.3324/haematol.2022.282653
   Google Scholar
• Xiong Y, Mouginot M, Reppel L, et al. Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15. Immunol Res. 2017;65(6):1130–1138. doi: 10.1007/s12026-017-8955-6
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–553. doi: 10.1056/NEJMoa1910607
   PubMed Web of Science ®Google Scholar